Login to Your Account



'Valley of death' bridged? Biopharma, academia look to 'real-world' solutions

By Marie Powers
News Editor

Tuesday, June 16, 2015
PHILADELPHIA – For decades, young biotechs have circled the so-called "Valley of Death," trying not to fall into the funding chasm that can occur during the period between discovery and clinical proof of concept – the critical milestone when most venture capital (VC) firms are willing to get on board.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription